The second article in the medical journal, by Dr. Eric Topol of the Cleveland Clinic, criticizes the FDA for not requiring Merck to do studies investigating heart problems with Vioxx even though hints of danger appeared years ago.
 When Merck voluntarily withdrew Vioxx, FDA officials said heart problems were unique to that drug and that the mechanism underlying them wasn't known.